心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2018 EHRA/ESC共识：抗心律失常药物的临床用药及临床决策制定

2018-02-09 欧洲心律学会 Europace. 2018 Feb 9.

抗心律失常药物临床用药临床决策制定

2018年2月，欧洲心律学会(EHRA)、欧洲心脏病学会(ESC)心血管药理学工作组共同发布了抗心律失常药物的临床用药及临床决策制定共识。 文章主要内容包括决定启动抗心律失常药物治疗以及随访，抗心律失常药物分类，治疗监测，个体化用药建议，应用抗心律失常药物预防高危患者猝死，抗心律失常药物作为设备和心律失常介入治疗的辅助，安全因素等。

中文标题：

2018 EHRA/ESC共识：抗心律失常药物的临床用药及临床决策制定

英文标题：

Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the He

发布机构：

欧洲心律学会

发布日期：

2018-02-09

简要介绍：

2018年2月，欧洲心律学会(EHRA)、欧洲心脏病学会(ESC)心血管药理学工作组共同发布了抗心律失常药物的临床用药及临床决策制定共识。 文章主要内容包括决定启动抗心律失常药物治疗以及随访，抗心律失常药物分类，治疗监测，个体化用药建议，应用抗心律失常药物预防高危患者猝死，抗心律失常药物作为设备和心律失常介入治疗的辅助，安全因素等。

 

拓展指南：与心律失常相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 EHRA/ESC共识：抗心律失常药物的临床用药及临床决策制定)] GetToolGuiderByIdResponse(projectId=1, id=570771c0015590ff, title=2018 EHRA/ESC共识：抗心律失常药物的临床用药及临床决策制定, enTitle=Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the He, guiderFrom=Europace. 2018 Feb 9., authorId=null, author=, summary=2018年2月，欧洲心律学会(EHRA)、欧洲心脏病学会(ESC)心血管药理学工作组共同发布了抗心律失常药物的临床用药及临床决策制定共识。 文章主要内容包括决定启动抗心律失常药物治疗以及随访，抗心律失常药物分类，治疗监测，个体化用药建议，应用抗心律失常药物预防高危患者猝死，抗心律失常药物作为设备和心律失常介入治疗的辅助，安全因素等。 , cover=, journalId=null, articlesId=null, associationId=206, associationName=欧洲心律学会, associationIntro=欧洲心律学会（EHRAE,uropean Heart Rhythm Association)是欧洲心脏病学会的分支，致力于心律失常的预防与管理，以减少心律失常对患者的影响,减少心源性猝死。官方杂志《欧洲心律失常杂志》影响因子为1.839, copyright=0, guiderPublishedTime=Fri Feb 09 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<P>2018年2月，欧洲心律学会(EHRA)、欧洲心脏病学会(ESC)心血管药理学工作组共同发布了抗心律失常药物的临床用药及临床决策制定共识。 文章主要内容包括决定启动抗心律失常药物治疗以及随访，抗心律失常药物分类，治疗监测，个体化用药建议，应用抗心律失常药物预防高危患者猝死，抗心律失常药物作为设备和心律失常介入治疗的辅助，安全因素等。</P> <P> </P>拓展指南：<strong>与<font color=red>心律失常</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=2c5a71c001555576" title="中国儿童心律失常导管消融专家共识解读" target=_blank>中国儿童心律失常导管消融专家共识解读</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=85ae41c0015a55a1" title="中国儿童心律失常导管消融专家共识" target=_blank>中国儿童心律失常导管消融专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=3e0311c001515525" title="2017 AHA/ACC/HRS指南：室性心律失常的管理和心脏性猝死的预防" target=_blank>2017 AHA/ACC/HRS指南：室性心律失常的管理和心脏性猝死的预防</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=2d4a41c001a4e184" title="权威指南共识推荐：心律失常的管理及治疗" target=_blank>权威指南共识推荐：心律失常的管理及治疗</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=4efb51c001a4e0f8" title="《自主神经系统相关心律失常管理专家共识》解读" target=_blank>《自主神经系统相关心律失常管理专家共识》解读</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E5%BF%83%E5%BE%8B%E5%A4%B1%E5%B8%B8" target=_blank>有关心律失常更多指南</a></ul>, tagList=[TagDto(tagId=20420, tagName=抗心律失常药物), TagDto(tagId=54296, tagName=临床用药), TagDto(tagId=70505, tagName=临床决策制定)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=2, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6595, appHits=705, showAppHits=6, pcHits=4571, showPcHits=2287, likes=144, shares=24, comments=6, approvalStatus=1, publishedTime=Sat Feb 24 20:24:20 CST 2018, publishedTimeString=2018-02-09, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sat Feb 24 20:24:20 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 20:11:52 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 EHRA/ESC共识：抗心律失常药物的临床用药及临床决策制定)])
2018 EHRA/ESC共识：抗心律失常药物的临床用药及临床决策制定
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=970140, encodeId=ed259e014086, content=非常想学习，可惜打不开, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d351382253, createdName=dingyuexia, createdTime=Tue Jun 01 19:41:29 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291107, encodeId=deec29110efb, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Feb 26 15:01:50 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290618, encodeId=1756290618e9, content=不错的文章.94和31, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sat Feb 24 22:57:56 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290610, encodeId=bf31290610e6, content=不错的文章.值得推荐, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sat Feb 24 22:33:47 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290603, encodeId=981a290603a1, content=2018年2月.欧洲心律学会(EHRA).欧洲心脏病学会(ESC)心血管药理学工作组共同发布了抗心律失常药物的临床用药及临床决策制定共识. 文章主要内容包括决定启动抗心律失常药物治疗以及随访.抗心律失常药物分类.治疗监测.个体化用药建议.应用抗心律失常药物预防高危患者猝死.抗心律失常药物作为设备和心律失常介入治疗的辅助.安全因素等., beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sat Feb 24 22:07:36 CST 2018, time=2018-02-24, status=1, ipAttribution=)]
    2021-06-01 dingyuexia

    非常想学习，可惜打不开

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=970140, encodeId=ed259e014086, content=非常想学习，可惜打不开, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d351382253, createdName=dingyuexia, createdTime=Tue Jun 01 19:41:29 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291107, encodeId=deec29110efb, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Feb 26 15:01:50 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290618, encodeId=1756290618e9, content=不错的文章.94和31, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sat Feb 24 22:57:56 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290610, encodeId=bf31290610e6, content=不错的文章.值得推荐, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sat Feb 24 22:33:47 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290603, encodeId=981a290603a1, content=2018年2月.欧洲心律学会(EHRA).欧洲心脏病学会(ESC)心血管药理学工作组共同发布了抗心律失常药物的临床用药及临床决策制定共识. 文章主要内容包括决定启动抗心律失常药物治疗以及随访.抗心律失常药物分类.治疗监测.个体化用药建议.应用抗心律失常药物预防高危患者猝死.抗心律失常药物作为设备和心律失常介入治疗的辅助.安全因素等., beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sat Feb 24 22:07:36 CST 2018, time=2018-02-24, status=1, ipAttribution=)]
    2018-02-26 131****1460

    学习了受益匪浅

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=970140, encodeId=ed259e014086, content=非常想学习，可惜打不开, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d351382253, createdName=dingyuexia, createdTime=Tue Jun 01 19:41:29 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291107, encodeId=deec29110efb, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Feb 26 15:01:50 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290618, encodeId=1756290618e9, content=不错的文章.94和31, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sat Feb 24 22:57:56 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290610, encodeId=bf31290610e6, content=不错的文章.值得推荐, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sat Feb 24 22:33:47 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290603, encodeId=981a290603a1, content=2018年2月.欧洲心律学会(EHRA).欧洲心脏病学会(ESC)心血管药理学工作组共同发布了抗心律失常药物的临床用药及临床决策制定共识. 文章主要内容包括决定启动抗心律失常药物治疗以及随访.抗心律失常药物分类.治疗监测.个体化用药建议.应用抗心律失常药物预防高危患者猝死.抗心律失常药物作为设备和心律失常介入治疗的辅助.安全因素等., beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sat Feb 24 22:07:36 CST 2018, time=2018-02-24, status=1, ipAttribution=)]
    2018-02-24 1e1b8538m79(暂无匿称)

    不错的文章.94和31

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=970140, encodeId=ed259e014086, content=非常想学习，可惜打不开, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d351382253, createdName=dingyuexia, createdTime=Tue Jun 01 19:41:29 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291107, encodeId=deec29110efb, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Feb 26 15:01:50 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290618, encodeId=1756290618e9, content=不错的文章.94和31, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sat Feb 24 22:57:56 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290610, encodeId=bf31290610e6, content=不错的文章.值得推荐, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sat Feb 24 22:33:47 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290603, encodeId=981a290603a1, content=2018年2月.欧洲心律学会(EHRA).欧洲心脏病学会(ESC)心血管药理学工作组共同发布了抗心律失常药物的临床用药及临床决策制定共识. 文章主要内容包括决定启动抗心律失常药物治疗以及随访.抗心律失常药物分类.治疗监测.个体化用药建议.应用抗心律失常药物预防高危患者猝死.抗心律失常药物作为设备和心律失常介入治疗的辅助.安全因素等., beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sat Feb 24 22:07:36 CST 2018, time=2018-02-24, status=1, ipAttribution=)]
    2018-02-24 131****2916

    不错的文章.值得推荐

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=970140, encodeId=ed259e014086, content=非常想学习，可惜打不开, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d351382253, createdName=dingyuexia, createdTime=Tue Jun 01 19:41:29 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291107, encodeId=deec29110efb, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Feb 26 15:01:50 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290618, encodeId=1756290618e9, content=不错的文章.94和31, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sat Feb 24 22:57:56 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290610, encodeId=bf31290610e6, content=不错的文章.值得推荐, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sat Feb 24 22:33:47 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290603, encodeId=981a290603a1, content=2018年2月.欧洲心律学会(EHRA).欧洲心脏病学会(ESC)心血管药理学工作组共同发布了抗心律失常药物的临床用药及临床决策制定共识. 文章主要内容包括决定启动抗心律失常药物治疗以及随访.抗心律失常药物分类.治疗监测.个体化用药建议.应用抗心律失常药物预防高危患者猝死.抗心律失常药物作为设备和心律失常介入治疗的辅助.安全因素等., beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sat Feb 24 22:07:36 CST 2018, time=2018-02-24, status=1, ipAttribution=)]
    2018-02-24 有备才能无患

    2018年2月.欧洲心律学会(EHRA).欧洲心脏病学会(ESC)心血管药理学工作组共同发布了抗心律失常药物的临床用药及临床决策制定共识. 文章主要内容包括决定启动抗心律失常药物治疗以及随访.抗心律失常药物分类.治疗监测.个体化用药建议.应用抗心律失常药物预防高危患者猝死.抗心律失常药物作为设备和心律失常介入治疗的辅助.安全因素等.

    0